Afamelanotide - Human Pigmentation Clinical Trials - Arizona

Arizona

A 1991 study of α-MSH in 28 "healthy white men" who used a "high-potency sunscreen during the trial" concluded that "Human skin darkens as a response to a synthetic melanotropin given by subcutaneous injection. Skin tanning appears possible without potentially harmful exposure to ultraviolet radiation."

A 1997 pharmacokinetic trial to establish efficacy of peptide administration compared intravenous, oral and subcutaneous routes. The study found that, "subcutaneous administration is an efficacious method of delivering melanotan".

A 1999 clinical dose ranging study in "eight male volunteers with 'tannable' skin types III-IV" given α-MSH (Melanotan-I) determined that an optimal dose for ten daily subcutaneous injections is 0.16 mg/kg per day.

A 2000 study to determine increases of eumelanin expression in seven, "normal volunteers" administered α-MSH concluded that, "the tanning induced by Melanotan in the face and forearm is associated with a significant increase in the eumelanin content of the human skin."

Three 2004 Phase I clinical trials sought to establish the safety of α-MSH therapy combined with UV-B light or sunlight exposure. The researchers determined, "Melanotan-1 can be safely combined with UV-B light or sunlight and appears to act synergistically in the tanning response to light." This trial was funded by the National Cancer Institute.

Read more about this topic:  Afamelanotide, Human Pigmentation Clinical Trials

Famous quotes containing the word arizona:

    Desert rains are usually so definitely demarked that the story of the man who washed his hands in the edge of an Arizona thunder shower without wetting his cuffs seems almost credible.
    —Administration in the State of Ariz, U.S. public relief program (1935-1943)

    The Great Arizona Desert is full of the bleaching bones of people who waited for me to start something.
    Robert Benchley (1889–1945)